Scientific and Medical Advisors

 

  • Flint Beal, MD, Neurology
    • Beal is an internationally recognized authority on neurodegenerative disorders. He is University Professor at the Brain and Mind Institute of Weill Cornell Medical College.
    • He was Professor of Neurology at the Harvard Medical School and Chief of the Neurochemistry laboratory at Massachusetts General Hospital before moving to Cornell.
    • Beal’s research has focused on the mechanism of neuronal degeneration in Alzheimer’s Disease, Huntington’s Disease, Parkinson’s Disease and amyotrophic lateral sclerosis (ALS).
    • Beal is the author or co-author of more than 500 scientific articles and more than 125 books, book chapters and reviews. He serves on the editorial boards of seven journals, the Journal of Neurochemistry, the Annals of Neurology, Journal of Molecular Neuroscience, Experimental Neurology and Neurobiology of Disease.
    • He has served on the Council and as Vice President of the American Neurological Association and on the Science Advisory Committees of the Hereditary Disease Foundation, Huntington’s Disease Society of America, Parkinson’s Disease Study Group, Parkinson’ Disease Foundation, Bachman-Strauss Foundation, The ALS Association, and the American Health Assistance Foundation. Dr. Beal is also a member of the Institute of Medicine of the National Academy of Sciences.
    • He received his M.D. from the University of Virginia, completed his internship and first year residency in Medicine at New York-Cornell before completing his residency in Neurology at The Massachusetts General Hospital.

  • Edwin H. Kolodny, M.D., Neurology

    • Kolodny was the Bernard A. and Charlotte Marden Professor of Neurology and Chairman at the NYU School of Medicine. He was also the vice-Chairman of the Executive Committee of the Medical Board of the Tisch Hospital, Co-Chairman of the Executive Advisory Committee of the General Clinical Research Center and Director of the Neurology Service at NYU Medical Center.
    • His medical interests include: Neurology, Neurogenetics, Developmental Disabilities, Inborn Errors of Metabolism, and Neurodegenerative Diseases.His Neurogenetics Laboratory at NYU studied the biochemical and molecular causes of inherited diseases and more effective means for their treatment. In the past few years, his laboratory characterized a variety of novel mutations responsible related to lysosomal storage diseases and related conditions.
    • He received his MD from New York University, completed his residency at NYU, Bellevue and Massachusetts General Hospital, Neurology and also completed a Fellowship in Neurology at the National Institute of Mental Health.

  • Don Mahuran, Ph.D., Genetics & Genome Biology

    • Mahuran recently retired as a Senior Scientist in the Research Institute of the Hospital for Sick Children (HSC) and a Professor in the department of Laboratory Medicine and Pathobiology at the University of Toronto, Canada.
    • His basic research carried out worldwide over the last forty years has made possible the development of novel therapeutic approaches for the treatment of several of lysosomal storage diseases.
    • He received his PhD from the University of Windsor, in Windsor, Ontario, Canada, completed his postdoctoral training at the Division of Neurosciences at The Hospital for Sick Children (SickKids).

  • Claire Henchcliffe

    • Vice Chair for Clinical Research in Neurology and the director of the Parkinson’s and Movement Disorders Institute at Weill Cornell Medical Center in New York City.
    • She read for her BA in Biochemistry and completed her graduate thesis at the University of Oxford in the UK.
    • Post-doctoral training in genetics and neuroscience at the University of Cambridge, UK, and the University of California at Berkeley, California.
    • Dr. Henchcliffe received her medical degree from the College of Physicians and Surgeons of Columbia University in New York City. She completed both her internship and residency in neurology, and subsequently a fellowship in movement disorders at Columbia Presbyterian Medical Center’s Neurological Institute.
    • Her current research focuses on developing new treatments for Parkinson’s disease, and she has a specific interest in the potential for cell-based therapies.
    • She has been an investigator and on the steering committees for multiple clinical trials in Parkinson’s disease, and is the Weill Cornell site Principal Investigator for the NIH-funded NeuroNEXT clinical trial network.

  • Steve Pasternak

    • Scientist, Robarts Research Institute
    • Director, Cognitive Neurology and Alzheimer’s Disease Research Centre, Parkwood Institute
    • SB Massachusetts Institute of Technology Chemical Engineering
    • SB Massachusetts Institute of Technology Life Sciences
    • MD CM McGill University
    • PhD McGill University
    • FRCP(C) (Neurology)June 1995, McGill University Faculty of Medicine
    • His clinic at the Cognitive Neurology and Alzheimer’s Disease Research Centre at Parkwood Hospital I specialize in the diagnosis and treatment of Neurodegenerative diseases, with a focus on Alzheimer’s disease, Lewy Body Disease, Parkinson’s Disease Dementia
    • Launched a Phase 2 Clinical Trial of Ambroxol in Parkinson’s Disease Dementia, and participate in academic and industry-sponsored clinical trials.